Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
Medical Decision Making
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kent, D. L.
Right arrow Articles by Fihn, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kent, D. L.
Right arrow Articles by Fihn, S. D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

A Model for Planning Optimal Follow-up for Outpatients on Warfarin Anticoagulation

Daniel L. Kent

Domokos Vermes

Mary McDonell

Jorja Henikoff

Stephan D. Fihn

Patients taking warfarin for long-term anticoagulation require frequent clinic visits to monitor the prothrombin time ratio (PTR), a measure of blood clotting. A dynamic stochastic model using nonlinear optimization was developed to select follow-up visit intervals that minimize the overall costs of patient care. Assuming that fluctuations in a patient's PTR behave as a random diffusion process, future PTR fluctuations are unknown, except as revealed by past PTRs. To determine the incidence and costs of complications in relation to PTR, the authors reviewed the charts of 216 patients who had 719 patient-years of follow-up with 695 trivial, significant, life-threatening, or fatal complications. They modeled the relationship between costs of complications and deviation of the PTR from the therapeutic target as a fourth-order convex polynomial. The model is used to compute the interval to the next follow-up visit to minimize accumulated potential costs. Variables in the optimization are the cost of a mon itoring visit and the expected costs of complications. The latter are derived from the current PTR, the variability of the patient's past PTR values, the number of past PTRs available, and the target PTR for the patient. No attempt is made to predict the level of the next PTR or suggest adjustments in the warfarin dose. Shorter follow-up is recommended for patients who have histories of large fluctuations in past PTRs and for patients with few prior PTR determinabons. As visits accumulate, the patient's degree of variability can be estimated more accurately and visit intervals adjusted accordingly The scheduling method balances costs to the health care system of monitoring each patient against the expected costs of complications. This approach has the potential to reduce the number of monitoring visits necessary for safe management of anticoagulated patients with stable PTRs and to improve control among unstable patients. Key words: warfarin; anticoagulation, ambulatory care; follow-up studies; stochastic processes. (Med Decis Making 1992;12:132-141)

Medical Decision Making, Vol. 12, No. 2, 132-141 (1992)
DOI: 10.1177/0272989X9201200206


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
ChestHome page
J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti
Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 160S - 198S.
[Abstract] [Full Text] [PDF]


Home page
Int J Qual Health CareHome page
R. Tennant, M. A. Mohammed, J. J. Coleman, and U. Martin
Monitoring patients using control charts: a systematic review
Int. J. Qual. Health Care, August 1, 2007; 19(4): 187 - 194.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. Ansell, J. Hirsh, L. Poller, H. Bussey, A. Jacobson, and E. Hylek
The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 204S - 233S.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
R. H. White, T. McKittrick, J. Takakuwa, C. Callahan, M. McDonell, S. Fihn, and National Consortium of Anticoagulation Clinics
Management and Prognosis of Life-threatening Bleeding During Warfarin Therapy
Arch Intern Med, June 10, 1996; 156(11): 1197 - 1201.
[Abstract] [PDF]


Home page
Arch Intern MedHome page
The Stroke Prevention in Atrial Fibrillation Inves
Bleeding During Antithrombotic Therapy in Patients With Atrial Fibrillation
Arch Intern Med, February 26, 1996; 156(4): 409 - 416.
[Abstract] [PDF]


Home page
Arch Intern MedHome page
L. K. Gottlieb and S. Salem-Schatz
Anticoagulation in Atrial Fibrillation: Does Efficacy in Clinical Trials Translate Into Effectiveness in Practice?
Arch Intern Med, September 12, 1994; 154(17): 1945 - 1953.
[Abstract] [PDF]